Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Pancreatic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 10Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Locally Advanced Rectal Cancer 6Carcinoma, Non-Small-Cell Lung 6Liver Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Sarcoma 4Melanoma 4Lung Neoplasms 4Gastrointestinal Stromal Tumors 4Endometrial Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Neoplasms 2Mesothelioma 2

Interventions

Gemcitabine 2spartalizumab 1sargramostim 1folfirinox 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Pancreaticoduodenectomy 1Magnetic Resonance Spectroscopy 1Leucovorin 1Laparoscopy 1Fluorouracil 1Drug Therapy 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Adenocarcinoma × spartalizumab × Gastrointestinal × Clear all
NCT05607953 2025-07-04

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

TriSalus Life Sciences, Inc.

Phase 1 Active not recruiting
60 enrolled
Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡